These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 7836917)

  • 1. Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice.
    Baskar S; Glimcher L; Nabavi N; Jones RT; Ostrand-Rosenberg S
    J Exp Med; 1995 Feb; 181(2):619-29. PubMed ID: 7836917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules.
    Baskar S; Clements VK; Glimcher LH; Nabavi N; Ostrand-Rosenberg S
    J Immunol; 1996 May; 156(10):3821-7. PubMed ID: 8621919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of MHC Class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells.
    Ostrand-Rosenberg S; Baskar S; Patterson N; Clements VK
    Tissue Antigens; 1996 May; 47(5):414-21. PubMed ID: 8795142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MHC class II-transfected tumor cells induce long-term tumor-specific immunity in autologous mice.
    Baskar S; Azarenko V; Garcia Marshall E; Hughes E; Ostrand-Rosenberg S
    Cell Immunol; 1994 Apr; 155(1):123-33. PubMed ID: 8168141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules.
    Baskar S; Ostrand-Rosenberg S; Nabavi N; Nadler LM; Freeman GJ; Glimcher LH
    Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5687-90. PubMed ID: 7685909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity.
    Armstrong TD; Clements VK; Martin BK; Ting JP; Ostrand-Rosenberg S
    Proc Natl Acad Sci U S A; 1997 Jun; 94(13):6886-91. PubMed ID: 9192661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor cells expressing major histocompatibility complex class II and B7 activation molecules stimulate potent tumor-specific immunity.
    Baskar S; Nabavi N; Glimcher LH; Ostrand-Rosenberg S
    J Immunother Emphasis Tumor Immunol; 1993 Oct; 14(3):209-15. PubMed ID: 8297902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MHC class II and CD80 tumor cell-based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain.
    Ilkovitch D; Ostrand-Rosenberg S
    Cancer Immunol Immunother; 2004 Jun; 53(6):525-32. PubMed ID: 14730400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rejection of mouse sarcoma cells after transfection of MHC class II genes.
    Ostrand-Rosenberg S; Thakur A; Clements V
    J Immunol; 1990 May; 144(10):4068-71. PubMed ID: 2332639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrovirus-mediated gene transfer of B7-1 and MHC class II converts a poorly immunogenic neuroblastoma into a highly immunogenic one.
    Heuer JG; Tucker-McClung C; Gonin R; Hock RA
    Hum Gene Ther; 1996 Nov; 7(17):2059-68. PubMed ID: 8934220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors.
    Townsend SE; Su FW; Atherton JM; Allison JP
    Cancer Res; 1994 Dec; 54(24):6477-83. PubMed ID: 7527298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-specific immunity can be enhanced by transfection of tumor cells with syngeneic MHC-class-II genes or allogeneic MHC-class-I genes.
    Ostrand-Rosenberg S; Roby C; Clements VK; Cole GA
    Int J Cancer Suppl; 1991; 6():61-8. PubMed ID: 1906055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2.
    Chen PW; Ananthaswamy HN
    J Immunol; 1993 Jul; 151(1):244-55. PubMed ID: 8326126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after MHC class I gene transfection.
    Weber JS; Jay G; Tanaka K; Rosenberg SA
    J Exp Med; 1987 Dec; 166(6):1716-33. PubMed ID: 3500265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency.
    Cayeux S; Richter G; Becker C; Beck C; Aicher A; Pezzutto A; Dörken B; Blankenstein T
    Eur J Immunol; 1997 Jul; 27(7):1657-62. PubMed ID: 9247574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer immunotherapy by antisense suppression of Ii protein in MHC-class-II-positive tumor cells.
    Qiu G; Goodchild J; Humphreys RE; Xu M
    Cancer Immunol Immunother; 1999 Dec; 48(9):499-506. PubMed ID: 10602887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B7-1 (CD80)-gene transfer combined with interleukin-12 administration elicits protective and therapeutic immunity against mouse hepatocellular carcinoma.
    Tatsumi T; Takehara T; Kanto T; Kuzushita N; Ito A; Kasahara A; Sasaki Y; Hori M; Hayashi N
    Hepatology; 1999 Aug; 30(2):422-9. PubMed ID: 10421650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines.
    Pulaski BA; Ostrand-Rosenberg S
    Cancer Res; 1998 Apr; 58(7):1486-93. PubMed ID: 9537252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transfection of major histocompatibility complex class I and class II genes causes tumour rejection.
    Ostrand-Rosenberg S; Clements VK; Thakur A; Cole GA
    J Immunogenet; 1989; 16(4-5):343-9. PubMed ID: 2639907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrosarcoma cells expressing allogeneic MHC Class II antigens induce protective antitumor immunity.
    Leach DR; Callahan GN
    J Immunol; 1995 Jan; 154(2):738-43. PubMed ID: 7814880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.